# A Trial of NT-I7 in COVID-19 (SPESELPIS)

> **NCT04501796** · PHASE1 · TERMINATED · sponsor: **NeoImmuneTech** · enrollment: 7 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Double-Blind NT-I7
- **DRUG:** Double-Blind Placebo

## Key facts

- **NCT ID:** NCT04501796
- **Lead sponsor:** NeoImmuneTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-27
- **Primary completion:** 2021-07-21
- **Final completion:** 2023-02-23
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study was halted due to lack of patient population resulting in slow enrollment.
- **Last updated:** 2023-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501796, "A Trial of NT-I7 in COVID-19 (SPESELPIS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04501796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*